Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Label Randomized Controlled Dose Escalating Phase II Study of AS1411 Combined With Cytarabine in the Treatment of Patients With Primary Refractory or Relapsed Acute Myeloid Leukemia

NCT00512083 is registered in ClinicalTrials.gov with Antisoma Research as lead sponsor.

NCT NCT00512083
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00512083 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Label Randomized Controlled Dose Escalating Phase II Study of AS1411 Combined With Cytarabine in the Treatment of Patients With Primary Refractory or Relapsed Acute Myeloid Leukemia
Lead sponsor
Antisoma Research
Phase
Phase 2
Overall status
Completed
Start date
July 31, 2007
Completion date
Not reported
Enrollment
70 (estimated)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

leukemia, myeloid